摘要
目的:观察非小细胞肺癌患者外周血红细胞(RBC)己糖激酶(HK)的活性水平以及化疗对它的影响,进一步探讨其临床意义。方法:用酶联法对38例非小细胞肺癌患者的外周血红细胞己糖激酶(RBCHK)水平进行检测,并与正常对照组进行对比研究。结果:38例非小细胞肺癌患者总体RBCHK活性显著高于正常对照组(P<0.01);且Ⅰ、Ⅱ期肺癌患者(共8例)RBCHK活性亦显著高于正常对照组(P<0.01);Ⅲ、Ⅳ期肺癌患者(共30例)RBCHK活性水平显著高于Ⅰ、Ⅱ期患者(P<0.01);非小细胞肺癌患者外周血RBCHK水平与病理分型无明显相关性;肺癌化疗后,RBCHK明显低于化疗前水平(P<0.01)。结论:外周血RBCHK活性水平与非小细胞肺癌的诊断、分期、预后等都有一定的关系,但与病理分型没有明显的相关性。
Objective：To detect the expression of erythrocytic hexokinase（ RBC H K） in the patients with non-small cell lung cancer （NSCLC） and to find the chemotherapeutic effect on it. Methods ：The expression of RBC HK was examined by enzyme-connected method in 38 patients with NSCLC. Twenty common cases served as controls. Results：The levels of RBC HK in patients with NSCLC were much higher than those in the normal group （ P 〈0. 01 ） ; The levels of RBC HK in stage Ⅰ , Ⅱwere apparently higher than those in the normal group too; The activities of RBC HK in stage Ⅲ, Ⅳ were much higher than those in stage Ⅰ , Ⅱ（ P 〈 0. 01 ） ; The activities of RBC HK in the patients who received chemotherapy were apparently lower than those before chemotherapy（ P 〈0. 01 ）. There was no significant difference between the expression of RBC HK in squamous carcinoma and adenocarcinoma. Conclusion ： Detection the activities of peripheral blood RBC HK might be helpful for diagnosis, staging and prognosis of patients with non- small cell lung cancer,but it has no relationship with the pathologic typing.
出处
《临床肿瘤学杂志》
CAS
2007年第2期91-93,共3页
Chinese Clinical Oncology
关键词
非小细胞肺癌
红细胞
己糖激酶
Non-small cell lung cancer
Erythrocyte
Hexokinase
